Completed PHASE3 INTERVENTIONAL 3-arm NCT00335166

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Sponsor: Solvay Pharmaceuticals

Conditions Early Stage Parkinson Disease

Interventions Pardaprunox Placebo Comparator pramipexole

Updated 7 times since 2017 Last updated: Apr 1, 2008 Started: Nov 30, 2006 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Early Stage Parkinson Disease and is currently completed. Solvay Pharmaceuticals leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Solvay Pharmaceuticals

Data source: Solvay Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aix-en-Provence, France , Albany, United States , Arcugnano (VI), Italy , Augusta, United States , Bangalore, India , Bangkok, Thailand , Barcelona, Spain , Bedford Park, Australia , Birmingham, United States and 71 more locations